- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Senate passes Drug Quality and Security Act
- Helping independents compete in specialty pharmacy, Cardinal Health launches new suite of services at RBC 2013
- Rite Aid posts third consecutive quarterly profit as company expands Wellness+
OSAKA, Japan — Drug makers Takeda Pharmaceutical and H. Lundbeck have applied with the Food and Drug Administration for a new drug to treat depression in adults.
Japan-based Takeda and Denmark-based Lundbeck announced the submission of a new drug application for Lu AA21004 (vortioxetine) for major depressive disorder.
"The prevalence and complexity of major depressive disorder remains a growing concern for physicians and those living with the condition," Takeda Global Research & Development Center president Azmi Nabulsi said. "This NDA submission is a critical milestone for Takeda and our partner, Lundbeck, demonstrating our commitment to those living with and treating this condition."